The acquisition will allow Amgen to additional its analysis and enhance the event of cancer-targeting therapies.
US multinational biotechnology firm Amgen has introduced the acquisition of most cancers drug discovery platform Darkish Blue Therapeutics in a deal valued at as much as $840m.
Established in 2020 and headquartered in Oxford, England, Darkish Blue Therapeutics develops cutting-edge precision oncology medicines. Through the acquisition Amgen can add to its portfolio “an investigational small molecule that targets and degrades two proteins (MLLT1/3) that drive particular varieties of acute myeloid leukemia (AML)”.
Based on Amgen, “Preclinical knowledge in leukemia fashions display promising anti-cancer exercise and mechanistic differentiation from presently obtainable therapies, establishing the rationale for single-agent and mixture use to beat remedy resistance and improve sturdiness of remission.”
Commenting on the announcement, Dr Jay Bradner, the manager vice chairman of analysis and improvement at Amgen, stated, “Acute myeloid leukemia stays one of the vital tough cancers to deal with, and we see an pressing want for brand spanking new mechanisms able to altering the trajectory of this illness.
“This acquisition enhances and extends our analysis in focused protein degradation and leukemia therapeutics, advancing our technique to speculate early in rising medicines for novel therapeutic targets. The adjacency of this programme to our thought-about experience in most cancers biology will propel MLLT1/3-targeting medicines to medical investigation for sufferers going through the difficult prognosis of AML.”
Alastair MacKinnon, the CEO of Darkish Blue Therapeutics, added, “Amgen has the experience, sources and dedication to speed up improvement of DBT 3757 to deal with sufferers with acute leukemia, together with these that don’t reply to present customary therapies.
“With its world-leading capabilities in oncology and deep expertise in growing, manufacturing and commercialising novel medicines, we’re assured that Amgen will construct on our pre-clinical work to carry DBT 3757 to the sufferers who urgently want new remedy choices.”
Late final 12 months, six researchers at Irish universities had been profitable in securing funds from the newest spherical of the European Analysis Council Consolidator Grants. One such challenge is being overseen by Dr Caroline Curtin on the RCSI College of Medication and Well being Sciences.
Curtin’s challenge, ‘Major bone most cancers scaffolds as managed launch non-viral gene supply platforms’, goals to develop next-generation therapies for main bone cancers. She stated, “This transformative know-how will present a extremely focused anti-cancer remedy choice for these aggressive and malignant cancers, whereas additionally selling bone restore.”
Don’t miss out on the data you might want to succeed. Join the Day by day Transient, Silicon Republic’s digest of need-to-know sci-tech information.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s developments as we speak: learn extra, subscribe to our publication, and grow to be a part of the NextTech group at NextTech-news.com
